Literature DB >> 15550678

Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected].

Christian Grimm1, Robert Kraft, Günter Schultz, Christian Harteneck.   

Abstract

TRPM3, a member of the melastatin-like transient receptor potential channel subfamily (TRPM), is predominantly expressed in human kidney and brain. TRPM3 mediates spontaneous Ca2+ entry and nonselective cation currents in transiently transfected human embryonic kidney 293 cells. Using measurements with the Ca2+-sensitive fluorescent dye fura-2 and the whole-cell patch-clamp technique, we found that D-erythro-sphingosine, a metabolite arising during the de novo synthesis of cellular sphingolipids, activated TRPM3. Other transient receptor potential (TRP) channels tested [classic or canonical TRP (TRPC3, TRPC4, TRPC5), vanilloid-like TRP (TRPV4, TRPV5, TRPV6), and melastatin-like TRP (TRPM2)] did not significantly respond to application of sphingosine. Sphingosine-induced TRPM3 activation was not mediated by inhibition of protein kinase C, depletion of intracellular Ca2+ stores, and intracellular conversion of sphingosine to sphingosine-1-phosphate. Although sphingosine-1-phosphate and ceramides had no effect, two structural analogs of sphingosine, dihydro-D-erythro-sphingosine and N,N-dimethyl-D-erythro-sphingosine, also activated TRPM3. Sphingolipids, including sphingosine, are known to have inhibitory effects on a variety of ion channels. Thus, TRPM3 is the first ion channel activated by sphingolipids.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550678     DOI: 10.1124/mol.104.006734

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  55 in total

Review 1.  Vanilloid and melastatin transient receptor potential channels in vascular smooth muscle.

Authors:  Scott Earley
Journal:  Microcirculation       Date:  2010-05       Impact factor: 2.628

Review 2.  International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family.

Authors:  Long-Jun Wu; Tara-Beth Sweet; David E Clapham
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 3.  Pharmacology of transient receptor potential melastatin channels in the vasculature.

Authors:  Alexander Zholos
Journal:  Br J Pharmacol       Date:  2010-03-05       Impact factor: 8.739

4.  Activation of steroid-sensitive TRPM3 channels potentiates glutamatergic transmission at cerebellar Purkinje neurons from developing rats.

Authors:  Paula A Zamudio-Bulcock; Julie Everett; Christian Harteneck; C Fernando Valenzuela
Journal:  J Neurochem       Date:  2011-09-28       Impact factor: 5.372

Review 5.  Function and pharmacology of TRPM cation channels.

Authors:  Christian Harteneck
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04       Impact factor: 3.000

Review 6.  Gating of TRP channels: a voltage connection?

Authors:  Bernd Nilius; Karel Talavera; Grzegorz Owsianik; Jean Prenen; Guy Droogmans; Thomas Voets
Journal:  J Physiol       Date:  2005-05-05       Impact factor: 5.182

Review 7.  The mammalian melastatin-related transient receptor potential cation channels: an overview.

Authors:  Robert Kraft; Christian Harteneck
Journal:  Pflugers Arch       Date:  2005-05-14       Impact factor: 3.657

Review 8.  Emerging roles of TRPM6/TRPM7 channel kinase signal transduction complexes.

Authors:  V Chubanov; M Mederos y Schnitzler; J Wäring; A Plank; T Gudermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04       Impact factor: 3.000

9.  C-type natriuretic peptide activates a non-selective cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptide C receptor-mediated signalling.

Authors:  R A Rose; N Hatano; S Ohya; Y Imaizumi; W R Giles
Journal:  J Physiol       Date:  2007-01-04       Impact factor: 5.182

Review 10.  TRP channels.

Authors:  Kartik Venkatachalam; Craig Montell
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.